Unicycive Therapeutics, Inc
Price
FilingsNewest: 8-K, Director or officer changeSep 29 →InsidersNo open-market buys or sales.→HoldersNantahala 10.1%BlackRock 5.1%Vanguard 3.8%→Financing →PeersClosest companies: CVKD, XFOR, SER→
From the filings
Figures
- Net income
- −$35.2Mlast 12 months
- Operating cash flow
- −$28.7Mlast 12 months
- Cash and equivalents
- $44.2Mat the last balance sheet
- Shares outstanding
- 27.9M shareson issue